Kymera Therapeutics, Inc.

KYMR · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.1%

Institutions117.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$39.21M	$47.07M	$46.83M	$72.83M	$34.03M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$349.40M	-$261.63M	-$161.26M	-$100.53M	-$46.30M
Operating income as a percentage of revenue.	-891.1%	-555.8%	-344.4%	-138.0%	-136.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$311.35M	-$223.86M	-$154.81M	-$100.22M	-$45.59M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.69	$-2.98	$-2.87	–	$-3.15
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.69	$-2.98	$-2.87	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$357.01M	$120.26M	$68.39M	$47.98M	$31.00M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.74B	$978.03M	$603.13M	$605.90M	$487.18M
Everything the company owes — debt, unpaid bills, and other obligations.	$163.15M	$142.42M	$112.98M	$146.27M	$203.29M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.58B	$835.62M	$490.15M	$459.64M	$283.89M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$232.89M	-$194.50M	-$153.09M	-$128.95M	$88.13M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.45M	$12.84M	$2.84M	$1.60M	$9.10M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$234.34M	-$207.34M	-$155.92M	-$130.54M	$79.03M

	You	Peer avg
P/E	–	44.8
Revenue Growth	+466.4%	-24.6%
ROE	-24.2%	-41.4%

Kymera Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison